Marking the 40th anniversary of the Hatch-Waxman Amendments Tuesday (Sept. 24), the generic drug industry lobby released a white paper calling for Congress to pass bills that would allow the generic drug industry to remain viable in the face of declining prices, including reforms to the 340B program, pharmacy benefit managers practices and the Inflation Reduction Act. FDA Commissioner Robert Califf, meanwhile, told attendees at a workshop on generic drug development Tuesday the industry can help boost the competitiveness of...